We also have X and podcasts
Blood Biomarkers Detect Amyloid in Down Syndrome Independent of APOE Status
A new blood test reliably detects amyloid positivity in adults with Down syndrome, with performance independent of APOE ε4 carrier status—offering a scalable screening approach for Alzheimer’s-related pathology.
Background
Adults with Down syndrome have elevated risk for Alzheimer’s disease, often developing pathological changes earlier than the general population. Detecting amyloid burden typically requires expensive PET imaging. Blood-based proteomic biomarkers could streamline screening, but the role of genetic risk factors like APOE ε4 in this population was unclear.
Key Findings
- The plasma proteomic panel achieved 96% AUC in detecting amyloid PET positivity with or without APOE ε4 in the model
- Age, glial fibrillary acidic protein (GFAP), and phosphorylated tau-181 were the strongest predictive contributors
- APOE ε4 carrier status had minimal impact on overall model performance
- The study included 290 asymptomatic adults with Down syndrome using SIMOA technology to measure plasma biomarkers
Why It Matters
Unlike in the general population, APOE ε4 status appears less critical for predicting amyloid burden in Down syndrome. Instead, neuroinflammation markers and age are more relevant. This high-accuracy blood test offers a cost-effective alternative to PET for clinical triage, disease monitoring, and Alzheimer’s clinical trial recruitment.
Limitations
The cross-sectional design provides associations at a single timepoint without establishing causality or clinical progression prediction. The model’s generalizability to other populations requires independent validation.
Original paper: The association between APOE ε4 carrierships and the detection of amyloid positivity using an Alzheimer’s disease proteomic blood test in asymptomatic Down syndrome. — Alzheimer’s & dementia: the journal of the Alzheimer’s Association. 10.1002/alz.71338
